Advanced Adult Primary Liver Cancer Clinical Trial
Official title:
An Randomized and Controlled Study of Hepatic Arterial Infusion of Oxaliplatin and Fluorouracil Treatment of Advanced Primary Liver Cancer After TACE
To investigate the therapy effect and security of oxaliplatin and fluorouracil on with or without concomitant vascular invasion and extrahepatic metastases unresectable advanced primary liver cancer
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT00787787 -
Sunitinib Malate and Capecitabine in Treating Patients With Unresectable or Metastatic Liver Cancer
|
Phase 2 | |
| Completed |
NCT00052364 -
Oxaliplatin in Treating Patients With Liver Cancer
|
Phase 2 | |
| Completed |
NCT01229111 -
Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary Cancers
|
Phase 2 | |
| Completed |
NCT00107536 -
Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer
|
Phase 2 | |
| Completed |
NCT02072356 -
Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot be Removed by Surgery
|
Early Phase 1 | |
| Completed |
NCT00604721 -
Selumetinib in Treating Patients With Locally Advanced or Metastatic Liver Cancer
|
Phase 2 | |
| Completed |
NCT00101036 -
Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By Surgery
|
Phase 2 | |
| Completed |
NCT00028496 -
Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer
|
Phase 1 | |
| Completed |
NCT01766219 -
CPI-613 in Treating Patients With Advanced or Metastatic Bile Duct Cancer That Cannot Be Removed By Surgery
|
Phase 1/Phase 2 | |
| Terminated |
NCT00427973 -
AZD2171 in Treating Patients With Locally Advanced Unresectable or Metastatic Liver Cancer
|
Phase 2 | |
| Completed |
NCT00321594 -
Belinostat in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
|
Phase 1/Phase 2 | |
| Terminated |
NCT00087191 -
EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer
|
N/A | |
| Completed |
NCT00006016 -
Thalidomide and Chemoembolization With Doxorubicin in Treating Patients With Liver Cancer That Cannot be Removed by Surgery
|
Phase 2 | |
| Completed |
NCT01643499 -
Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies
|
Phase 1 | |
| Completed |
NCT00639509 -
IMC-A12 in Treating Patients With Advanced Liver Cancer
|
Phase 2 | |
| Completed |
NCT00083226 -
Doxorubicin and Bortezomib in Treating Patients With Liver Cancer
|
Phase 2 | |
| Completed |
NCT00033462 -
Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder Cancer
|
Phase 2 | |
| Completed |
NCT01666756 -
Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer
|
Phase 1 | |
| Active, not recruiting |
NCT02119065 -
Pilot Study to Assess Lung Shunting of Yttrium-90 Microspheres Using PET/CT
|
||
| Withdrawn |
NCT01859182 -
Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By Surgery
|
Phase 2 |